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Table 1
OA-Related Mean Cumulative One-Year Costs by Joint Location, Age, and
Comorbidity
Subgroup Total
Medical*
Inpatient Outpatient Physical or
Occupational
Therapy
Pharmacy
Overall $8,644 $3,533 $4,921 $265 $2,179
Joint location
Knee $9,466 $4,178 $5,093 $292 $2,086
Hip $12,478 $7,473 $4,818 $295 $2,047
Hand $6,705 $1,505 $5,004 $221 $2,256
Age group, y
18–44 $10,857 $3,398 $7,070 $440 $1,794
45–64 $12,799 $5,400 $7,144 $395 $2,258
65y $3,510 $1,429 $2,002 $84 $2,156
Comorbidity
Hypertension $8,917 $3,855 $4,857 $232 $2,519
CVD $10,844 $4,993 $5,575 $157 $3,150
Diabetes $10,815 $4,709 $5,859 $242 $3,358
CVD ¼ cardiovascular disease; OA ¼ osteoarthritis.
*Total medical costs are equal to the sum of inpatient, outpatient, and emergency
room costs, excluding physical or occupational therapy and pharmacy costs.
yCosts for patients 65 are underestimated because payments observed here are
supplements to Medicare.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S210clinically diagnosed knee or hip OA, or participants with knee or hip
pain for more than one month who were likely to have OA. Outcome
measures were measurements that evaluated physical functioning and
pain. The included articles were assessed for bias and the results were
summarized according to best evidence synthesis.
Results: Of the 9068 studies that were found, 27 articles were included.
In patients with knee OA, the average course of physical functioning
varied between studies (inconsistent evidence). The samewas found for
the average course of knee pain in studies with a follow up period
shorter than three years. Only one study examined the course of pain
over a longer period, and found an improvement in pain over six years
(weak evidence). In addition, in patients with hip OA the average course
of physical functioning in studies with a follow up period shorter than
three years was found to be stable (strong evidence). Because only one
study examined the course of physical functioning over a period longer
than three years, weak evidence was found for a stable course over 5
years. No publications were found that examined the course of pain in
patients with hip OA. With regard to prognostic factors, in patients with
knee OA strong evidence was found for various prognostic factors for
future deterioration in physical functioning i.e. older age, a low to
middle education level, higher body mass index, high morbidity count,
use of pain medication, greater difﬁculties with physical functioning at
baseline, lower knee extension strength, higher pain intensity, patella-
femoral joint compression, lower walking ability, poor mental health
and a low vitality. With regard to predictors for future knee pain, a
longer symptom duration, bilateral knee symptoms and a higher level
of pain at baseline were found to predict future pain in patients with
knee OA (strong evidence). In hip OA strong evidence was found that a
high morbidity count and a low vitality increase the likelihood of
deterioration of physical functioning. No publications were found on
prognostic factors for future pain.
Conclusion: The average course of physical functioning and pain in
patients with knee OAwas found to be variable between studies. In hip
OA, the long-term course of physical functioning was found to be stable.
In comparison to a previous review stronger evidence was found for a
number of variables to be prognostic factors of physical functioning and
pain, including demographic factors, clinical factors, knee character-
istics and psychosocial factors. Knowledge on prognostic factors can be
used to inform patients on the likely course of their condition and to
adapt treatment according to the prognosis. Although many studies
have been carried out recently, more studies with a longitudinal design
are warranted, especially in patients with hip OA.
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Purpose: Osteoarthritis (OA) is the most common form of arthritis and
the leading cause of working age disabilities. Over 27 million US adults
have clinical OA, and different types of burdens exist based on the
disease stages and locations. The burden of OA by joint location, age, or
comorbidity has not been well studied. The objective of this study was
to assess the excess health care resource use and costs attributable to
OA by joint location, age, and comorbidity in a privately insured
population.
Methods: 428,084 OA patients aged18 were selected from a US-based
employer claims database (1999–2011). Controls were selected from the
same database by matching OA patients 1:1 by age, gender, index date,
and follow-up time to patients who never had OA in their claims his-
tories. Descriptive analyses were used to compare baseline character-
istics and study period medical resource use and costs, inﬂated to 2011
US dollars using annual medical Consumer Price Index data (Bureau of
Labor Statistics). Statistical comparisons were made using McNemar’s
test for categorical variables and the Wilcoxon signed-rank test for
continuous variables.
Results: Among all the OA patients studied,181,379 had a primary claim
of knee OA; 48,617 had hip OA; 29,340 had hand OA; and 30,549 had
spine OA. The average age of OA patients was 63 years and 59% were
female. At baseline, OA patients tended to have a greater comorbidity
burden than controls (P< 0.001). The occurrence of the 4most common
comorbidities between the OA group and controls were hypertension
(45% vs 30%, respectively), cardiovascular disease (14% vs 8%,respectively), diabetes (16% vs 10%, respectively), and depression (8% vs
4%, respectively). OA patients aged 18 incurred total annual medical
costs of $8,644 vs $2,273 in controls (P < 0.001). 20% of all OA patients
had at least 1 primary joint arthroplasty, 1% had a revision joint
arthroplasty, and 2% had arthrodesis. The cost per surgery ranged from
$16,000 to $25,000. On average, a hip arthroplasty cost $18,425 and a
knee arthroplasty cost $17,433. Annual pharmacy cost was $2,179 for OA
patients and $1,096 for controls. OA-related health care costs are
summarized by joint locations, age, and comorbidity in Table 1.Con-Conclusions: Patients with OA incur greater medical and pharmacy
costs than those without OA. The burden of OA varies substantially by
joint location. Surgical procedures are the most signiﬁcant cost among
all categories, and therefore is also one of the main drivers of the total
cost. In contrast, pharmacy costs are rather small due to no disease-
modifying OA drug (DMOAD) available. Hand OA had lower costs than
knee and hip OA due to lack of DMOADs and effective surgery. In
summary, OA presents a great disease and economic burden. The cur-
rent treatment options are limited to generic symptom-modifying
drugs and late-stage surgical management of the disease, but the latter
is only available for certain joints.
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Purpose: Osteoarthritis (OA) produces pain and mobility limitations
which require intensive primary care management. Once the disease
reaches an advanced stage, total hip replacements (THRs) are very
effective at improving patients’ health and reducing demand for pri-
mary care resources. The costs of managing OA before surgery, however,
have not been thoroughly explored leading to most assessments of
THRs to exclude these costs from economic models. We aimed to
describe the use of primary care resources attributable to OA in the UK
and to estimate the costs borne by the NHS for these services.
Methods: We used data from the General Practice Research Database
(GPRD, now CPRD) of all patients with a primary THR before 31
December 2006 who were 45 years of age or older at the time of
operation. The data set included the clinical history of up to ﬁve controls
for each THR case. Controls had no record of hip arthroplasty, OA or
arthritis, and were matched to cases by GP practice, gender and age.
Data included consultations with GPs, nurses, consultants and allied
health professionals (AHP) as well as prescription of selected 25 drugs
grouped into categories as NSAIDs, opioid and non-opioid analgesics,
